Research programme: H1/NK1 antagonists - Sanofi-Aventis/Inflazyme

Drug Profile

Research programme: H1/NK1 antagonists - Sanofi-Aventis/Inflazyme

Alternative Names: H1/NK1 antagonists research programme - Aventis/Inflazyme; Histamine H1/neurokinin NK1 antagonists research programme - Aventis/Inflazyme; Research programme: histamine H1/neurokinin NK1 antagonists - Aventis/Inflazyme

Latest Information Update: 18 Mar 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Class
  • Mechanism of Action Histamine H1 receptor antagonists; Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic conjunctivitis; Allergic rhinitis

Most Recent Events

  • 12 Jun 2008 Discontinued - Preclinical for Allergic conjunctivitis in North America (Ophthalmic)
  • 12 Jun 2008 Discontinued - Preclinical for Allergic rhinitis in North America (PO)
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top